Correspondence 0001387131-23-008773 from Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Date: July 26, 2023 · CIK: 0000887247 · Accession: 0001387131-23-008773
AI Filing Summary & Sentiment
File numbers found in text: 333-273233
Letter
Re: Adamis Pharmaceuticals Corporation
July 26, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-273233
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as placement agent for the above-referenced offering, hereby join in the request of Adamis Pharmaceuticals Corporation (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 9:00 AM, Eastern Time, on July 28, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Weintraub Tobin, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.
We, the undersigned, as placement agent, have complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
MAXIM GROUP LLC
Show Raw Text
CORRESP
1
filename1.htm
July 26, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Adamis Pharmaceuticals Corporation
Registration Statement on Form S-1
File No. 333-273233
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act
of 1933, as amended (the “Act”), we, as placement agent for the above-referenced offering, hereby join in the request
of Adamis Pharmaceuticals Corporation (the “Company”) for acceleration of the effective date of the above-named Registration
Statement so that it becomes effective at 9:00 AM, Eastern Time, on July 28, 2023, or as soon thereafter as practicable, or at such other
time as the Company or its outside counsel, Weintraub Tobin, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, please be advised
that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others
prior to the requested effective time of the Registration Statement.
We, the undersigned, as placement agent, have complied
and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
MAXIM GROUP LLC
By:
/s/ Clifford A. Teller
Name:
Clifford A. Teller
Title:
Co-President